CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ADVL1515 | COG | A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors | Pediatric CIRB | Completed |
| 10273 | ETCTN | A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10061 | ETCTN | A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10246 | ETCTN | A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10601 | ETCTN | A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10508 | ETCTN | A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10464 | ETCTN | A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10031 | ETCTN | A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer | Adult CIRB - Early Phase Emphasis | Completed |
| 10563 | ETCTN | A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin (Doxil®) in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas | Adult CIRB - Early Phase Emphasis | Available to Open |
| ADVL1615 | COG | A Phase 1 Study of Pevonedistat (MLN4924, IND # 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Available to Open |